AbbVie Invests $195 Million to Boost U.S. API Manufacturing Capacity

AbbVie Expands API Manufacturing Facility in North Chicago

In a significant move to strengthen its pharmaceutical capabilities, AbbVie (NYSE: ABBV) has announced a $195 million investment aimed at expanding its manufacturing of active pharmaceutical ingredients (APIs) in North Chicago, Illinois. This expansion aligns with AbbVie's strategic commitment to invest over $10 billion in the U.S. over the next decade, focusing on innovation and expanding critical manufacturing capabilities.

The new facility will bolster AbbVie's ability to produce essential components needed for effective medications. APIs are crucial as they are the active substances in a drug that provide its therapeutic effects. With the expansion, AbbVie intends to enhance its chemical synthesis capabilities, supporting the domestic production of medications across a range of therapeutic areas including neuroscience, immunology, and oncology.

Robert A. Michael, AbbVie's Chairman and CEO, stated, "Over the next decade, AbbVie will expand production of API, drug product, peptides, and medical devices in the U.S. to support future medical breakthroughs. This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."

Scheduled to begin construction in the fall of 2025, the new site is expected to be fully operational by 2027. Once completed, this facility will expand AbbVie's existing U.S. manufacturing footprint, which currently supports over 6,000 jobs across its 11 manufacturing sites in the nation, along with thousands more at supplier locations.

This latest announcement not only reflects AbbVie's long-term commitment to American manufacturing but also reinforces its presence in Illinois, where the company is headquartered with a workforce of more than 11,000 employees. Governor JB Pritzker highlighted the significance of this investment, acknowledging that it underscores Illinois' world-class workforce, infrastructure, and robust research institutions that appeal to pharmaceutical giants.

"AbbVie's decision to expand its manufacturing footprint in Illinois is a testament to our state's capabilities and its positioning as a leader in biomanufacturing. This investment not only creates jobs but also paves the way for innovation that will result in next-generation therapeutics," noted Governor Pritzker.

AbbVie's dedication to developing innovative medicines is driven by its mission to address serious health issues that patients face today and anticipate future medical challenges. The company focuses on several therapeutic areas, including immunology, oncology, neuroscience, and more through its Allergan Aesthetics portfolio.

As AbbVie prepares to embark on this significant expansion project, the pharmaceutical community and patients alike will be looking forward to seeing how this initiative will enhance the availability and development of cutting-edge medical treatments designed to improve patient outcomes.

For more details about AbbVie's endeavors and its commitment to healthcare innovation, visit AbbVie’s official website or follow them on social media platforms like LinkedIn, Facebook, and Twitter.